MAGE-A3 is a CTA expressed in different cancer types, especially, melanoma and non-small cell lung cancer (NSCLC) [6, 7], and is a promising candidate TAA for vaccine development. This evidence concerns the gene MAGEA3 and non-small cell lung carcinoma.